NCT06411314View on ClinicalTrials.gov

Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis

PHASE3CompletedINTERVENTIONAL
Enrollment

218

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

July 26, 2023

Study Completion Date

September 22, 2023

Conditions
Vulvovaginal Candidiasis, Genital
Interventions
COMBINATION_PRODUCT

Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories

1 suppository once daily at bedtime for 6 days

DRUG

Lactulose 300 mg vaginal suppositories

1 suppository once daily at bedtime for 6 days

DRUG

Pimafucin® (natamycin) 100 mg vaginal suppositories

1 suppository once daily at bedtime for 6 days

Trial Locations (1)

Unknown

Department of Reproductive Medicine and Surgery at the A.I. Evdokimov Moscow State Medical and Dental University, Moscow

All Listed Sponsors
lead

Avva Rus, JSC

INDUSTRY